The presence of gastric acid plays a critical role in the mechanisms of NSAIDs/aspirin-associated gastric and duodenal mucosal injury and ulceration. The role of gastric acid and its relationship to NSAIDs/aspirin in mucosal damage, ulcer and ulcer complications continues to be an important concern because of the increasing worldwide use of NSAIDs and aspirin. Acid suppression continues to be an important prevention strategy for NSAID-associated gastric and duodenal ulcer and ulcer complications. While a coxib or an NSAID and PPI in combination are considered to have comparable safety profiles, the evidence from direct comparisons in high-risk patients is limited, and the cardiovascular safety of coxibs and NSAIDs remains a concern especially in patients with a high risk of cardiovascular disease. An evaluation of individual gastrointestinal and cardiovascular risks and benefits, selection of the most appropriate NSAID and dose for each particular patient should always be emphasized. Twice daily PPI is more appropriate to protect a patient who is taking NSAIDs twice daily. PPI co-therapy is still recommended in patients receiving dual antiplatelet treatment, although conflicting results have been reported about adverse drug interactions between PPIs and clopidogrel.

1.
Gustafson J, Welling D: ‘No acid, no ulcer’ – 100 years later: a review of the history of peptic ulcer disease. J Am Coll Surg 2010;210:110–116.
2.
Chan FK, Sung JJ: Role of acid suppressants in prophylaxis of NSAID damage. Best Pract Res Clin Gastroenterol 2001;15:433–445.
3.
Scarpignato C, Hunt RH: Non-steroidal anti-inflammatory drug-related injury to the gastrointestinal tract: clinical picture, pathogenesis, and prevention. Gastroenterol Clin North Am 2010;39:433–464.
4.
Huang JQ, Sridhar S, Hunt RH: Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 2002;359:14–22.
5.
Venerito M, Malfertheiner P: Interaction of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in gastric and duodenal ulcers. Helicobacter 2010;15:239–250.
6.
Lanas A, Hunt R: Prevention of anti-inflammatory drug-induced gastrointestinal damage: benefits and risks of therapeutic strategies. Ann Med 2006;38:415–428.
7.
Antithrombotic Trialists’ (ATT) Collaboration, Baigent C, Blackwell L, et al: Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009;373:1849–1860.
8.
Nishino M, Sugimoto M, Kodaira C, et al: Relationship between low-dose aspirin-induced gastric mucosal injury and intragastric pH in healthy volunteers. Dig Dis Sci 2010;55:1627–1636.
9.
Rostom A, Dube C, Wells G, et al: Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Library, 2007, issue 2.
10.
Nishino M, Sugimoto M, Kodaira C, et al: Preventive effects of lansoprazole and famotidine on gastric mucosal injury induced by low-dose aspirin in Helicobacter pylori-negative healthy volunteers. J Clin Pharmacol 2011;51:1079–1086.
11.
Padol IT, Hunt RH: Association of myocardial infarctions with COX-2 inhibition may be related to immunomodulation towards a Th1 response resulting in atheromatous plaque instability: an evidence-based interpretation. Rheumatology (Oxford) 2010;49:837–843.
12.
Chan FK, Lanas A, Scheiman J, et al: Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet 2010;376:173–179.
13.
Rostom A, Moayyedi P, Hunt R, Canadian Association of Gastroenterology Consensus Group: Canadian consensus guidelines on long-term non-steroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks. Aliment Pharmacol Ther 2009;29:481–496.
14.
Wang CC, Yuan Y, Chen Y, Hunt RH: Night-time pH holding time: what is hidden by the % of time pH ≤4? Am J Gastroenterol 2008;103(suppl 1):S51.
15.
Goldstein JL, Hochberg MC, Fort JG, et al: Clinical trial: the incidence of NSAID-associated endoscopic gastric ulcers in patients treated with PN-400 (naproxen + esomeprazole magnesium) vs. enteric-coated naproxen alone. Aliment Pharmacol Ther 2010;32:401–413.
16.
Lanas A: Gastrointestinal bleeding associated with low-dose aspirin use: relevance and management in clinical practice. Expert Opin Drug Saf 2011;10:45–54.
17.
Ng FH, Wong SY, Lam KF, et al: Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions. Gastroenterology 2010;138:82–88.
18.
Earnshaw SR, Scheiman J, Fendrick AM, et al: Cost-utility of aspirin and proton pump inhibitors for primary prevention. Arch Intern Med 2011;171:218–225.
19.
Bhatt DL, Scheiman J, Abraham NS, et al: ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am J Gastroenterol 2008;103:2890–2907.
20.
Gilard M, Arnaud B, Cornily JC, et al: Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 2008;51:256–260.
21.
Leontiadis GI, Yuan Y, Howden C: The interaction between PPIs and clopidogrel and upper gastrointestinal bleeding. Gastrointest Endosc Clin North Am 2011;21:637–656.
22.
Bhatt DL, Cryer BL, Contant CF, et al for the COGENT Investigators: Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 2010;363:1909–1917.
23.
Bardou M, Barkun AN: Preventing the gastrointestinal adverse effects of nonsteroidal anti-inflammatory drugs: from risk factor identification to risk factor intervention. Joint Bone Spine 2010;77:6–12.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.